Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer-Reference-Cited by-同舟云学术

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer

Published:2020-11-13 Issue:46 Volume:99 Page:e23053
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Choi Jin Hyuk,Jeon Chang Wan,Kim Young Ok,Jung Sungui

Funder

National Research Foundation of Korea

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference28 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas;Press;J Clin Oncol,1997

4. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system;Gown;Mod Pathol,2008

5. HER2 and responsiveness of breast cancer to adjuvant chemotherapy;Pritchard;N Engl J Med,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity;Cancers;2024-05-25

2. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China;World Journal of Surgical Oncology;2024-04-06

3. Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer;Diagnostic Pathology;2024-02-15

4. Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma;HISTOL HISTOPATHOL;2024

5. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results;Breast Cancer Research;2023-12-14